1182 K
20 pp.
View Document 
TitleProduction of Medical Radioisotopes in the ORNL High Flux Isotope Reactor (HFIR) for Cancer Treatment and Arterial Restenosis Therapy after PTCA
Author(s)Knapp, F. F. Jr.; Beets, A. L.; Mirzadeh, S.; Alexander, C. W.; Hobbs, R. L.
Publication DateJune 1998
Report NumberORNL/CP--97929
Unique IdentifierACC0024
Other NumbersCONF-980446--; Legacy ID: DE98003519; OSTI ID: 661540
Research OrgOak Ridge National Laboratory, TN (United States) [ORNL]
Contract NoAC05-96OR22464
Sponsoring OrgUSDOE Assistant Secretary for Human Resources and Administration, Washington, DC (DOE/HR)
Other Information13th Radiochemical Conference, Marianske Lazne (Czech Republic), 19-24 Apr 1998;
Subject22 Nuclear Reactor Technology; 55 Biology and Medicine, Basic Studies; Research, Test, Training, Production, Irradiation, Materials Testing Reactors; Unsealed Radionuclides in Therapy
KeywordsRadiopharmaceuticals; Isotope Production; HFIR Reactor; Experimental Data; Radiotherapy; Neoplasms; Skeletal Diseases; Vascular Diseases
Related Web PagesPeaceful Uses of the Atom
AbstractThe High Flux Isotope Reactor (HFIR) at the Oak Ridge National Laboratory (ORNL) represents an important resource for the production of a wide variety of medical radioisotopes. In addition to serving as a key production site for californium-252 and other transuranic elements, important examples of therapeutic radioisotopes which are currently routinely produced in the HFIR for distribution include dysprosium-166 (parent of holmium-166), rhenium-186, tin-117m and tungsten-188 (parent of rhenium-188). The nine hydraulic tube (HT) positions in the central high flux region permit the insertion and removal of targets at any time during the operating cycle and have traditionally represented a major site for production of medical radioisotopes. To increase the irradiation capabilities of the HFIR, special target holders have recently been designed and fabricated which will be installed in the six Peripheral Target Positions (PTP), which are also located in the high flux region. These positions are only accessible during reactor refueling and will be used for long-term irradiations, such as required for the production of tin-117m and tungsten-188. Each of the PTP tubes will be capable of housing a maximum of eight HT targets, thus increasing the total maximum number of HT targets from the current nine, to a total of 57. In this paper the therapeutic use of reactor-produced radioisotopes for bone pain palliation and vascular brachytherapy and the therapeutic medical radioisotope production capabilities of the ORNL HFIR are briefly discussed.
1182 K
20 pp.
View Document 

Some links on this page may take you to non-federal websites. Their policies may differ from this site.